Stout performed IPO readiness services for Evommune, a clinical stage biotechnology company that discovers and develops novel therapies to treat immune-mediated chronic inflammatory diseases.

We assisted the client’s management team with the preparation of its financial statements, which included its S-1.

Evommune was the first biotechnology IPO on the New York Stock Exchange in 2025.

Its pipeline includes a differentiated small molecule and biologic that target key drivers of chronic inflammatory diseases, with three ongoing Phase 2 trials in chronic spontaneous urticaria and atopic dermatitis indications.